

Guiding your patients through their treatment with DARZALEX FASPRO®

You play an important role in their treatment journey

An open dialogue with your patients may help them better understand their treatment plan and feel prepared in the regimen chosen by their doctor. This tool can help you talk about DARZALEX FASPRO® and answer questions about their diagnosis and treatment plan.

DARZALEX Faspro® (daratumumab and hyaluronidase-fihi) Injection for subcutaneous use | 1800mg/30,000units

About multiple myeloma About DARZALEX FASPRO® Clinical benefits Expectations for treatment Important Safety Information

Patient support

How to use this guide

There are 2 versions of this guide. One version is for you to share with your patients, either as a PDF via email, as a printout given in-office, or via screen sharing on a video call. This version is for healthcare providers only; do not share this with patients. Use this document as a reference for talking points and helpful tips when discussing DARZALEX FASPRO® with your patients.

This conversation guide covers a range of topics about multiple myeloma and DARZALEX FASPRO[®], including:

- What is multiple myeloma and how does it develop
- Approved regimens of DARZALEX FASPRO®
- How DARZALEX FASPRO® works
- Clinical studies for DARZALEX FASPRO®
- What to expect before, during, and after treatment
- Important Safety Information for DARZALEX FASPRO®
- Cost support

You can tailor the conversation to your patient's needs by scrolling between pages or using the buttons at the bottom to jump to new sections. Additional resources and a glossary are also available at the end of the guide. You may direct patients to this section for further information about DARZALEX FASPRO® and useful tools to help them on their treatment journey. Use these dots to keep track of how many pages are left in a section.

• • • • •

Short on time?

Use the navigation below to discuss what information you think is most important for your patient to know. The 15-minute and 30-minute buttons here and **at the top of every page** will also take you to recommended sections for patients who are starting treatment soon.

We have 15 minutes

We have 30 minutes

2N



About multiple myeloma About DARZALEX FASPRO® Clinical benefits

Expectations for treatment

Important Safety Information Patient support

Cover Page

START 15-MINUTE DISCUSSION

5

Use this page to discuss with patients where they are in their treatment journey.

Talking points

- Your journey is as unique as you are
- Your healthcare team shares your goal of treating your disease in the way that's best for you
 - This conversation will help you learn about DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and why your healthcare team believes this is the appropriate treatment for your multiple myeloma
- If you have any questions or concerns as we discuss DARZALEX FASPRO[®], feel free to ask them now or make note of them to bring to your next doctor's appointment. Remember, you are your own best advocate
- Any bolded terms you see throughout this guide are defined in the glossary at the end



🛛 Tip

Ask the patient if they have a support system in place. Having a friend or family member who can help run errands or a caregiver who can come to appointments and support their treatment journey may help ease the burden.



DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) injection for subcutaneous use 11800mo/30000units

About multiple myeloma

About DARZALEX FASPRO® Clinical benefits

Expectations for treatment

Important Safety Information

Patient support

What is multiple myeloma?

5

Direct patients to click on the About multiple myeloma button. Use this page to give a summary of how multiple myeloma develops and how it affects the body. If your patient is already familiar with this information, you may skip ahead to the About DARZALEX FASPRO® section.

C^L Key takeaway

Multiple myeloma affects plasma cells in bone marrow, which can lead to long-term damage and problems throughout the body.


Talking points

- Multiple myeloma is a blood cancer that affects a type of white blood cell called plasma cells
 - These cells are found mostly in the bone marrow, the soft substance inside some hollow bones where blood cells are made
- Normal, healthy plasma cells are responsible for producing antibodies
 - Antibodies are part of the immune system and help the body fight infections

- In multiple myeloma, the DNA, or genetic material, of plasma cells are damaged, causing them to overproduce
 - This can weaken the immune system and lead to the production of abnormal amounts of antibodies
 - These antibodies are called M-proteins
 - M-proteins are abnormal antibodies that don't help the body fight infections
 - High amounts of M-protein can damage the kidneys
 - These damaged or cancerous plasma cells rapidly spread and replace normal cells with tumors, usually in the bone marrow

🛞 What is multiple myeloma?

Multiple myeloma is a blood cancer that affects a type of white blood cell called a plasma cell. These white blood cells are found ne marrow, the soft substance inside some hollow bones where blood cells are made



4N



(F) About multiple myeloma

• 0

About **DARZALEX FASPRO®**

Clinical **benefits** **Expectations for** treatment

Important Safety Information

Patient

support

Staying on treatment

Use this page to discuss the possibility of multiple myeloma getting worse and how the doctor will manage the various stages.

C Key takeaway

Multiple myeloma can get worse over time, so it's important to stay on top of treatment and communicate with your doctor.

Talking points

DARZALEX Faspro®

(daratumumab and hyaluronidase-fihi)

Injection for subcutaneous use 1,800mg/30,000units

- Over time, multiple myeloma can get worse
- You may start to show more symptoms as the cancer spreads to different parts of the body
 - Depending on where the cancer spreads, you may experience different symptoms
- To experience the full benefits of your treatment plan, stay on treatment as directed by your doctor
- If you experience any negative side effects, let your doctor know immediately

(F)

About multiple

myeloma

- If you are experiencing reactions to the treatment, you and your doctor can decide next steps together

About

DARZALEX FASPRO®

Clinical

benefits

Expectations for

treatment

Important Safety

Information

🛞 Stay	ying on treatment
Over time, m	ultiple myeloma can get worse.
W	As multiple myeloma progresses, you may start to show more symptoms , or the cancer might start to spread and impact other parts of your body.
	To experience the full benefits of your treatment plan, it's important to receive treatment as directed by your doctor and stay on it as long as your doctor determines is appropriate.
	If you experience any negative side effects, let your doctor know immediately and you can decide on the next steps together.
Please <u>click here</u> to	read full Prescribing Information for DARZALEX FASPRO*. Please see additional Important Safety Information on pages <u>18-21</u> .
CARZALEX Fasp (deratureerate and heatureridae sector in solatorescore (URIng NRI	About multiple mystolene exponent About multiple battALEX MATRO* Clisical benefits Espectations for beatment Important Safety Patient Glossary

Patient

support

5 N

What is DARZALEX FASPRO®?

15-MINUTE DISCUSSION

30-MINUTE DISCUSSION

•••••

•••••

Direct patients to click on the About DARZALEX FASPRO® button. Use this page to discuss the patient's prescribed regimen with DARZALEX FASPRO®.

○[™] Key takeaway

DARZALEX FASPRO[®] is approved in several regimens for multiple myeloma. Let's talk about the one prescribed for your needs.

Talking points

- DARZALEX FASPRO[®] is a prescription medicine used to treat different types of patients with multiple myeloma
- It is given as a subcutaneous injection
 - That means DARZALEX FASPRO® is injected by your healthcare provider under the skin near your stomach
- Use the appropriate graphic to discuss your patient's regimen:
 - If you are newly diagnosed with multiple myeloma and cannot receive a type of transplant that uses your own stem cells (autologous stem cell transplant), you may receive DARZALEX FASPRO® in combination with Revlimid® (lenalidomide) and dexamethasone, in combination with Velcade® (bortezomib), melphalan, and prednisone
 - If you are newly diagnosed with multiple myeloma and can receive a type of transplant that uses your own stem cells (autologous stem cell transplant), you may receive DARZALEX FASPRO® in combination with Velcade® (bortezomib), thalidomide, and dexamethasone
 - If you have received at least 1 prior medicine to treat your multiple myeloma,

you may receive DARZALEX FASPRO® in combination with Revlimid® and dexamethasone, in combination with Pomalyst® (pomalidomide) and dexamethasone, or in combination with Velcade® and dexamethasone

- If you have received at least one prior medicine including lenalidomide and a proteasome inhibitor, you may receive DARZALEX FASPRO® in combination with pomalidomide and dexamethasone
- If you have received at least 3 prior medicines to treat your multiple myeloma, including an immunomodulatory agent, such as Revlimid[®], and a proteasome inhibitor (PI), such as Velcade[®], or did not respond to a PI and an immunomodulatory agent, you may receive DARZALEX FASPRO[®] as a monotherapy (by itself)
- You should also inform your patient that they should not receive DARZALEX FASPRO® if they've had a severe allergic reaction to DARZALEX FASPRO® or any of its ingredients
 - You should begin to review some of the Important Safety Information and let the patient know that you will be discussing it in more detail later

What is DARZALEX FASPRO®?

DARZALEX FASPRO® is a prescription medicine used to treat different types of patients with multiple myeloma. It is given by your healthcare provider as an injection in the subcutaneous tissue (the tissue under the skin) of the stomar



IMPORTANT SAFETY INFORMATION

De not nearly DAZIALER KARRO" il you have a history of a savere allergic traccion to darahmumab. hydrarolidase, or any of the ingredients in DARIALEX KARRO". See below for a complete list of lingredients in DARIALEX KARRO". Before you receive DAZIALEX KARRO", Hell you heditace provider abuit all of your medical conditions, including il you:

have a history of breathing problems
 have had shinales (herpes zoster)

DARZALEX Faspro* About multiple

Please click here to read full Prescribing Information for DARZALEX FASPRO®. Please see additional Important Safety Information on pages 18-21.



Tip

After you've discussed your patient's prescribed regimen, you may direct them to <u>www.darzalex.com/faspro</u> to download a treatment calendar for their regimen to plan their appointments.

6 N

DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) Injection for subcutaneous use [1,800mg/30,000units

About multiple myeloma About DARZALEX FASPRO®

• 0

Clinical benefits Expectations for treatment

Important Safety Information

Safety ion Patient support

How does DARZALEX FASPRO[®] work?



Use this page to explain the components of DARZALEX FASPRO® and how it treats multiple myeloma.

C^L Key takeaway

DARZALEX FASPRO® helps your own immune system identify and destroy multiple myeloma cells.

Talking points

- DARZALEX FASPRO® has 2 main ingredients:
 - Daratumumab, which is responsible for treating multiple myeloma
 - Hyaluronidase, which helps daratumumab to be injected into the skin and absorbed into the body. Hyaluronidase is what allows DARZALEX FASPRO® to be injected subcutaneously
- DARZALEX FASPRO® is not chemotherapy. It is an immunotherapy that uses your own body's immune system to fight multiple myeloma
- Here's how daratumumab fights the disease:
 - Multiple myeloma cells, like other types of cancer, can go unrecognized by your body, which allows cells to grow
 - Daratumumab is a monoclonal antibody. That means it attaches specifically to the CD38 protein found on the **surface of multiple myeloma cells**, as well as other types of cells such as red blood cells
 - Daratumumab works in a few different ways. It can directly kill multiple myeloma cells, or it can help the immune system identify cancerous cells and destroy them
 - Because of the way daratumumab works, it may also affect normal cells
- DARZALEX FASPRO[®] may cause serious reactions, including serious allergic reactions and other severe injection-related reactions, injection site reactions, decreases in blood cell counts, and changes in blood tests

\sim			
\$1	How does	DAR7ALEY	FASPRO [®] work?
	now does	DANLALLA	TASING WORK:



 have ever had or might now have a hepatitis B infection as DARZALEX FASPRO® could cause hepatitis B virus to become active nave even had at migin how have a nepanite simechan as been as how to be one can be been added and a set of the added and a set of the added added and the added adde of your eve





Tip

A video explanation of the mechanism of action for DARZALEX FASPRO® is available for healthcare professionals at www.darzalexhcp.com/faspro. Consider watching this video as a refresher before discussing how DARZALEX FASPRO® works with your patients.

7 N



About multiple myeloma

 (\mathbb{N}) About DARZALEX FASPRO®

••

Clinical **benefits** **Expectations for** treatment

Important Safety Information

Patient

support

Monotherapy study

Direct patients to click on the Clinical Benefits button in the navigation. Use this page to discuss the noninferiority study between DARZALEX FASPRO® and DARZALEX® (daratumumab). If your patient is already familiar and confident in the clinical benefits of DARZALEX FASPRO®, you may jump ahead to expectations for treatment.

○[⊥] Key takeaway

DARZALEX FASPRO® was compared in a clinical study with the intravenous formulation, DARZALEX®.

Talking points

- A clinical study evaluated how well DARZALEX FASPRO[®], a subcutaneous injection, works compared to DARZALEX[®], an intravenous infusion with the same ingredient that treats multiple myeloma
 - DARZALEX® is a proven treatment in multiple combinations for managing multiple myeloma
- In the study, patients with multiple myeloma had received at least 3 prior medicines or did not respond to a PI like Velcade[®] (bortezomib) or an immunomodulatory agent like Revlimid[®] (lenalidomide)
- 522 patients were enrolled in the study
 - 263 patients were given DARZALEX FASPRO® monotherapy
 - 259 patients were given DARZALEX® monotherapy
- The next page covers the results of the study

Monotherapy study

A clinical study confirmed that DARZALEX FASPRO® gave patients results comparable to the intravenous (IV) formulation of DARZALEV! (daratumumab) in treating multiple myeloma when used as **montherapy** (by itself). DARZALEX¹'s an (V Inixian with the some disease-fighting ingredient and DRAZLEX FASPO? Itab its proven effective in multiple combinations to fight multiple myeloma.

Patients in this study had multiple myeloma and: • Received at least 3 prior medicines OR

Did not respond to a proteasome inhibitor (PI) and an immunomodulatory agent



IMPORTANT SAFETY INFORMATION (CONT)

 are pregnant or plan to become pregnant. DARZALEX FASIPRO® may harm your unbam baby. Tell your healthcare provider right away if you become pregnant or think had you may be pregnant during treatment with DARZALEX FASIPRO".
 Fermales who are able to become pregnant should use an effective method of birth control (contraception) during treatment and for 3 months after your last dase of DARZALEX FASIPRO". Tak to your healthcare provider about birth control methods that you can use during this time.

Please click here to read full Prescribing Information for DARZALEX FASPRO®. Please see additional Important Safety Information on pages 18-21.

|--|

8 N

DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) Injection for subcutaneous use [1,800mg/30,000units

About multiple myeloma About DARZALEX FASPRO® Clinical benefits

Expectations for treatment Important Safety Information Patient support

t tt

Results from the monotherapy study

START 15-MINUTE Ο DISCUSSION

Use this page to discuss the results from the noninferiority study between DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and DARZALEX® (daratumumab).

C^L Key takeaway

This study confirmed that DARZALEX FASPRO® monotherapy delivers responses consistent with DARZALEX[®] monotherapy.

Talking points

- A similar proportion of patients responded to each treatment
 - About 4 of 10 patients responded to treatment with DARZALEX FASPRO®
 - About 4 of 10 patients responded to treatment with DARZALEX[®]
- DARZALEX FASPRO® delivered responses consistent with DARZALEX®, a well-studied, proven treatment for multiple myeloma

Now let's review how well DARZALEX FASPRO® works in combination with other medicines.

Results from the monotherapy study			
DARZALEX FASPRO® (monotherapy)	DARZALEX® (monotherapy)		
About 4 of 10 patients responded to featment with DARZALEX FASPRO*	About 4 of 10 patients responded to tradiment with DARZALEX*		
treated with DARZALEX*, a proven t	reatment for multiple myeloma		
^o Before starting DARZALEX FASPRO [®] in combination with lenalidomic to the instructions in the lenalidomide, thalidomide, or pomalidomi			
 The lenalidomide, thalidomide, and pomalidomide REMS have m preanancy testina, and blood donation for females who can bee 			
 For males who have female partners who can become pregnant 			
Please click here to read full Prescribing Information for DARZALEX FASPRO®. Ple	ase see additional Important Safety Information on pages <u>18-21</u> .		
CharZALEX Faspro* About multiple myeloma About DAEZALEX FASPRO* Clinical Denefits	Expectations for Important Safety Patient Glossary treatment Information		

9N



About multiple myeloma

About **DARZALEX FASPRO®**

 \bigcirc Clinical benefits ••••

Expectations for treatment

Important Safety Information

Patient

support

Combination therapy study

Use this page to discuss the study in which DARZALEX FASPRO® was evaluated in various combinations with other medicines for different patient types.

C^L Key takeaway

Studies have evaluated how well DARZALEX FASPRO® works in combination therapy. The details of one of these combination regimens is available here.



- A study confirmed that DARZALEX FASPRO® is effective when used in combination with other medicines
- This study evaluated 132 patients
 - 67 patients with newly diagnosed multiple myeloma who could not receive a transplant received DARZALEX FASPRO® in combination with Velcade®, melphalan, and prednisone
- 65 patients who had received at least 1 prior medicine to treat their multiple myeloma received DARZALEX FASPRO® in combination with Revlimid® and dexamethasone
- The next page covers the results of this study

I studies have evaluated combination therapie ued that DARIALEX FASPRO® is effective when v and DRd results are shown here). 13 patients in	sed in combination with other medicines
DVMP	DRd
With newly diagnosed multiple	Who received at least
myeloma unable to have a transplant	1 prior medicine
DARZALEX FASPRO® + Velcade® (bortezomib)	DARZALEX FASPRO® + Revlimid® (lenalidomide)
+ melphalan + prednisone	+ dexamethasone
67 patients	65 patients

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medic

Please click here to read full Pre tion for DARTALEX FASPRO® Please see



10N



About multiple myeloma

About **DARZALEX FASPRO®**

 \bigcirc Clinical benefits $\bullet \bullet \bullet \circ$

Expectations for treatment

Important Safety Information

Patient

support

Results from the combination therapy study

Use this page to discuss the results of the combination therapy study.

C Key takeaway

DARZALEX FASPRO® was proven effective in combination with different medicines for different types of patients with multiple myeloma.



- About 9 of 10 patients responded to treatment with DARZALEX FASPRO[®] in combination with bortezomib, melphalan, and prednisone
- About 9 of 10 patients responded to treatment with DARZALEX FASPRO® in combination with lenalidomide and dexamethasone

If you want to know more about how well your prescribed regimen with DARZALEX FASPRO[®] will work, bring it up at your next doctor's appointment, or visit <u>www.darzalex.com/faspro</u>.

Result	About 9 of 1 to treatment in combinatia	he combi 0 patients responde with DARZALEX FASPRE n with bortezomib, nd prednisone	ed I	DRd	About 9 of 1 to treatment v	0 patients resp vith DARZALEX FA with lenalidom vasone	SPRO*
	will	rour doctor for more respond to your pre					
IMPORTANT SAFET							
How will I receive DAR							
 DARZALEX FASPRO[®] DARZALEX FASPRO[®] 							
 DARZALEX FASPRO[®] i DARZALEX FASPRO[®] i 			e provider as i	un injection under	the skin in the ston	iach aiea (abac	menj.
 Your healthcare prov 			oses as well as	how many treatm	ents you will receiv		
 Your healthcare pro- to help reduce the ri 	vider will give yo	u medicines before e	each dose of D	ARZALEX FASPRO®	and after each do	se of DARZALEX	
If you miss any appoin	tments, call you	r healthcare provider	as soon as po	ssible to reschedu	e your appointmer	nt.	
Please <u>click here</u> to read	full Prescribing In	formation for DARZALEX	FASPRO®. Please	e see additional Imp	ortant Safety Informa	ion on pages <u>18-1</u>	<u>n. 10</u>
DARZALEX Faspro [®]	About multiple myeloma	About DARZALEX FASPRO®	Q Clinical benefits	Expectations for treatment	Important Safety Information	Patient support	Glossary

11 N



About multiple myeloma About DARZALEX FASPRO® Q Clinical benefits

Expectations for treatment

Important Safety Information

Patient

Patient support

Treatment checklist for DARZALEX FASPRO®

15-MINUTE DISCUSSION

()

30-MINUTE DISCUSSION

This page is a checklist that patients may refer to when preparing for their treatment plan with DARZALEX FASPRO®.

Ialking points

- This page has important steps you should take before, during, and after the day of your injection of DARZALEX FASPRO®
- As we read through these together, make note of any questions you have and we will discuss it in more detail on the following pages

Tell your doctor about:	Wear comfortable clothing that is loose around the waist
All of your medical conditions	
	Set aside enough time
 All of the medications you are taking 	 Take the medications your doctor will give you prior to the injection
Ask your doctor about your treatment goals with DARZALEX FASPRO®. For example:	 Tell your healthcare providers and personnel at blood transfusion centers that you are taking DARZALEX FASPRO®
How will you know this treatment is working?	
What response are you hoping to see with DARZALEX FASPRO®	After your injection Pay attention to how you feel
How long should I expect to stay on this treatment regimen?	 Tell your doctor immediately if you experience any side effects or reactions
may temporarily stop or completely stop treatment with DARZALE or get medical help right away if you get any of these symptoms	th can hoppen with DA&ZLAEX FASPRO". Your healthcare provider XFASPRO" if your healthcare provider during or after an injection of DA&ZLAEX FASPRO". the blood (thypoid) = high blood pressure s or initiation = eye pain = chest pain nose = nousea = blurred vision = vomiting = chilis
ease click here to read full Prescribing Information for DARZALEX FASPRO®	Please see additional Important Safety Information on pages <u>18-21</u> .

Tip

Advise patients that they may want to save this checklist and add any questions they may have, and bring it to their next doctor's appointment.

12N



About multiple myeloma About DARZALEX FASPRO® Clinical benefits

Expectations for treatment

Important Safety Information

Patient support

nt ort

Before the injection

30-MINUTE DISCUSSION

Direct patients to click on the Expectations for treatment button in the navigation. Use this page to discuss what the patient should do before starting treatment with DARZALEX FASPRO[®].

O^{LL} Key takeaway

Tell your doctor about all of your medical conditions and any prescription or over-the-counter medicines, vitamins, or supplements that you take.

Talking points

- Let's now talk about what you can expect before, during, and after treatment with DARZALEX FASPRO®
- Before you receive your first injection of DARZALEX FASPRO[®], make sure you tell your healthcare provider, such as me or the doctor, about all of your medical conditions, including if you:
 - Have a history of **breathing problems**
 - Have had shingles (herpes zoster)
 - Have ever had or might now have a hepatitis
 B infection as DARZALEX FASPRO® could cause hepatitis B virus to become active again. Your healthcare provider will check you for signs of this infection before, during, and for some time after treatment with DARZALEX FASPRO®. Tell your healthcare provider right away if you get worsening tiredness or yellowing of your skin or white part your eyes
 - Are pregnant or plan to become pregnant.
 DARZALEX FASPRO® may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think that

you may be pregnant during treatment with DARZALEX FASPRO $\ensuremath{^{\!\circ}}$

- Females who are able to become pregnant should use an effective method of birth control (contraception) during treatment and for 3 months after your last dose of DARZALEX FASPRO®. Talk to your healthcare provider about birth control methods that you can use during this time
- Before starting DARZALEX FASPRO® in combination with lenalidomide, thalidomide, or pomalidomide, females and males must agree to the instructions in the lenalidomide, thalidomide, or pomalidomide REMS program
 - The lenalidomide, thalidomide, and pomalidomide REMS have more information about effective methods of birth control, pregnancy testing, and blood donation for females who can become pregnant
 - For males who have female partners who can become pregnant, there

💋 Before your injection

Before you receive DARZALEX FASPRO®, tell your healthcare provider:

✓ Have a history of breathing problems	 Prescription and over-the-counter medicines
✓ Have had shingles (herpes zoster)	✓ Vitamins
✓ Have ever had or might have a hepatitis B infection	✓ Herbal supplements
✓ Are pregnant or plan to become pregnant	
\checkmark Are breastfeeding or plan to breastfeed	
For additional information about how these	
conditions are affected by or impact treatment with	
DARZALEX FASPRO®, download the patient brochure	
at <u>www.darzalex.com/faspro</u> .	
ORTANT SAFETY INFORMATION (CONT)	
ection site reactions. Skin reactions at or near the injection site (
RZALEX FASPRO". Symptoms at the site of injection may include ese reactions sometimes happen more than 24 hours after an in	itching, swelling, bruising, pain, rash, bleeding, or redness of the skir iection of DARZALEX FASPRO®.
	Please see additional Important Safety Information on pages 18-21.

is information in the lenalidomide, thalidomide, and pomalidomide, REMS about sperm donation and how lenalidomide, thalidomide, and pomalidomide can pass into human semen

 Are breastfeeding or plan to breastfeed. It is not known if DARZALEX FASPRO® passes into your breast milk. You should not breastfeed during treatment with DARZALEX FASPRO®. Talk to your healthcare provider, such as me or the doctor, about the best way to feed your baby during treatment with DARZALEX FASPRO®

Tell your healthcare provider about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements.



DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) Injection for subcutaneous use [1,800mg/30,000units

About multiple myeloma About DARZALEX FASPRO® Clinical benefits Expectations for treatment

Important Safety Information Patient support

Preparing for the injection

15-MINUTE DISCUSSION

Use this page to discuss how the patient can prepare for their first injection of DARZALEX FASPRO®. If the patient is familiar with this information, you may skip to the next page.

C^L Key takeaway

On the day of your injection, wear comfortable clothing and make sure you set aside enough time for your doctor's appointment.

Talking points

- Is this the first time you are receiving treatment with DARZALEX FASPRO®? If so, let's talk about how you can prepare
- the waist. Your healthcare provider will inject DARZALEX FASPRO[®] about 3 inches to the left or right of the belly button
- Set aside enough time. We will want you to stay afterward to monitor for any reactions to the injection
- We will give you medicines to help reduce the side effects to the injection, including:
 - Antihistamines to prevent an allergic reaction
 - Corticosteroids to prevent inflammation
- Acetaminophen or a similar medicine to reduce any fever

- We will give you a physical exam before the injection, including checking your pulse and blood pressure
- Wear comfortable clothing that is loose around
 Make sure you tell your healthcare providers and personnel at blood transfusion centers that you are taking DARZALEX FASPRO®
 - DARZALEX FASPRO[®] can affect the results of blood tests to match your blood type
 - These changes can last for up to 6 months after your final dose of DARZALEX FASPRO®
 - We will do blood tests to match your blood type before you start treatment with DARZALEX FASPRO®
 - Tell all healthcare providers you are receiving DARZALEX FASPRO® before you receive a blood transfusion

Preparing for your injection	
If this is the first time you are receiving treatment with DARZALEX FASP need to do to prepare. Here is some information that may help.	"RO", you may have questions about what it's like, and what you
Wear comfortable clothing that is loose around the weist: DARZALEX FASPRO* is injected about 3 inches to the left or right of the belly button.	You will be given a physical exam before the injection: This includes checking your pulse and blood pressure.
Set aside enough time: For the first few injections, your healthcare provider may want you to stay afterward to monitor for a reaction to the injection.	Tell your healthcare provider and blood transfusion centers/personnel that you are taking DARZALEX FASPRO®.
You will be given medicines to help reduce the risk of side effects to the injection, such as:	DARZALEX FASPRO® can affect the results of blood tests to match your blood type. These changes can last for up to 6 months
Antihistamines to prevent an alleraic reaction	after your final dose of DARZALEX FASPRO". Your healthcare
Corticosteroids to prevent inflammation	provider will do blood tests to match your blood type before you start treatment with DARZALEX FASPRO®. Tell all your healthcare
Acetaminophen or similar medicine to reduce fever	start treatment with DAKALEX FASTRO [®] , lell all your nearthcare providers that you are being treated with DARZALEX FASPRO [®] before receiving blood transfusions.
IMPORTANT SAFETY INFORMATION (CONT)	
 Decreases in blood cell counts. DARZALEX FASPRO® can decrease v called platelets, which help to clot blood. Decreases in blood cell a Your healthcare provider will check your blood cell counts during to you develop fever or have signs of bruising or bleeding. 	counts are common with DARZALEX FASPRO® but can be severe.
Please click here to read full Prescribing Information for DARZALEX FASPRO®. Pl	lease see additional Important Safety Information on pages <u>18-21</u> . <u>13</u>
DARZALEX Faspro* About multiple About Clinical Clinical University of Darzalex resources (University of the State of Darzalex resources (University of the State of Darzalex resources of University of Darzalex resources of Darzalex reso	





About multiple myeloma

About **DARZALEX FASPRO®** Clinical **benefits**

(L) **Expectations for** treatment ••••0000

Important Safety Information

Patient

support

During the injection

Use this page to discuss what the patient can expect during the injection and how DARZALEX FASPRO® will be administered.

O[™] Key takeaway

DARZALEX FASPRO® is injected in about 3 to 5 minutes.

Talking points

- During the injection, your healthcare provider will draw DARZALEX FASPRO® into a needle
- They will select where to inject and prepare the chosen area, rotating injection sites in the **stomach area** each time you receive an injection
- The injection takes about **3 to 5 minutes** to be given. It is injected into the tissue under the skin of the stomach
 - Note that 3 to 5 minutes does not include all aspects of treatment. We will ask you to stay
 in the office so we can monitor for any reactions to the injection
- If you feel any discomfort during the injection, let us know right away

🧭 During your inj	ection	
Tour healthcare provider will prepare the injection	2 Vour healthcare provider will determine where to hijked and prepare the chosen area, rotaling injection alises in the stamosch area each time you receive an injection	The injection takes about 3 to 5 minutes to be given. ² The medicine is injected in the subcutaneous tissue (the fissue under the skip) of the storned.
IMPORTANT SAFETY INFORMATION	. ,	
for up to 6 months after your final dose (RO® can affect the results of blood tests to matc of DARZALEX FASPRO®. Your healthcare provider RZALEX FASPRO®. Tell all of your healthcare prov sod transfusions.	will do blood tests to match your blood
The most common side effects of DARZAN decreased red blood cell counts.	LEX FASPRO® when used alone include cold-like	symptoms (upper respiratory infection) and
Please click here to read full Prescribing Inform	nation for DARZALEX FASPRO®. Please see additional In	nportant Safety Information on pages <u>18-21</u> .
COARZALEX FCISpro* About multiple (doub.mambe and inplanmicipal-fift) myeloma Department industries (Utime Statistics	About Clinical Expectations for treatment to the second se	Important Safety Patient Gloss Information support

Tip

A video explaining how DARZALEX FASPRO® is administered is available for healthcare professionals on **www.darzalexhcp.com/faspro**. You may find it useful to review this video prior to discussing DARZALEX FASPRO® with patients.

15N



About multiple myeloma About DARZALEX FASPRO® Clinical benefits Expectations for treatment

Important Safety Information

Patient support

After the injection

30-MINUTE DISCUSSION

Use this page to discuss what patients should expect after receiving an injection of DARZALEX FASPRO®.

C Key takeaway

After the injection, you will be monitored for any reactions.

Talking points

- After the injection, pay attention to how you feel and let the healthcare staff know about any discomfort, especially during the first and second injections
 - Discomfort may mean you are having a reaction to the treatment
- If you have a history of severe allergic reactions to daratumumab, hyaluronidase, or any of the ingredients in DARZALEX FASPRO®, let me know now or before you receive your first injection of DARZALEX FASPRO®
- We may ask you to stay in the office after you receive the injection to watch for any side effects
- Serious allergic reactions and reactions due to release of certain substances by your body (systemic) that can lead to death, can happen with DARZALEX FASPRO®
 - Tell your healthcare provider or get medical help right away if you get any

of these symptoms during or after an injection of DARZALEX FASPRO®: shortness of breath or trouble breathing, dizziness or lightheadedness (hypotension), cough, wheezing, heart beating faster than usual, low oxygen in the blood (hypoxia), throat tightness, runny or stuffy nose, headache, itching, high blood pressure, nausea, vomiting, chills, fever, or chest pain

- Skin reactions at or near the injection site (local), including injection site reactions, can happen with DARZALEX FASPRO®
 - Symptoms at the site of injection may include itching, swelling, bruising, pain, rash, bleeding, or redness of the skin. These reactions sometimes happen more than 24 hours after an injection of DARZALEX FASPRO[®]

🧭 After your inje	ction		
especially during the Do not receive DARZ	first and second injections. It could in ALEX FASPRO® if you have a history of	ff know about any discomfort during o mean you may be having a reaction t f a severe allergic reaction to daratun for a complete list of ingredients in DAF	o the treatment. numab, hyaluronidase, or
Your healthcare provider may want you t	o remain in the office to watch for a	ny side effects.	
Serious allergic reactions and other sew certain substances by your body (system temporarily stop or completely stop treat medical help right away if you get any of	ic) that can lead to death can hap ment with DARZALEX FASPRO® if you	pen with DARZALEX FASPRO®. Your hea have a serious reaction. Tell your healt	althcare provider may
 shortness of breath or trouble breath dizziness or lightheadedness (hypote caugh wheezing heart beating faster than usual 			e o fever o chest pain o blurred vision
Injection site reactions. Skin reactions at a site (local), including injection site reaction DAR2ALEX FASPRO". Symptoms at the site itching, swelling, bruising, pain, rash, blee skin. These reactions sometimes happen i an injection of DARZALEX FASPRO*.	ns, can happen with of injection may include ding, or redness of the	It's important to stay on tree your doctor to feel the full I Discuss next steps with you experience any reactions t	r doctor if you
Following the injection, you will also be gi reduce the risk of delayed reactions due DARZALEX FASPRO [®] .			
Please click here to read full Prescribing Info	mation for DARZALEX FASPRO®. Please s	ee additional Important Safety Informatio	on on pages <u>18-21</u> . <u>15</u>
CARZALEX Faspro* (dedutements) ad helaritide-thi) system in december (URingStates) About multiple myeloma	About Clinical DARZALEX FASPRO® benefits	Expectations for treatment	Patient Glossary

- We will also give you oral corticosteroids to reduce the risk of delayed reactions from administration of DARZALEX FASPRO®
- It's important to stay on treatment as directed by your doctor to feel the full benefits of treatment
 - Discuss next steps with your doctor if you experience any reactions to the injection

16 N



About multiple myeloma

About DARZALEX FASPRO® Clinical benefits Expectations for treatment

Important Safety Information

/ P si

Patient support

Side effects

🧭 Side effects

30-MINUTE DISCUSSION

Use this page to discuss the rates of side effects of DARZALEX FASPRO[®] in clinical trials.

Talking points

- You may experience side effects from treatment
 - Side effects are an unwanted or unexpected treatment reaction to a drug that can occur anywhere due to the administration of treatment
- Reactions to the injection
 - Among all patients who participated in DARZALEX FASPRO® clinical studies, 9% of the 898 patients taking DARZALEX FASPRO® by itself or in combination with other multiple myeloma treatments experienced a reaction related to the injection
 - Most reactions were mild to moderate and occurred after the first injection
- 0.8% of the 898 patients experienced a severe injection-related reaction
 - Signs and symptoms included: shortness of breath or trouble breathing, dizziness or lightheadedness (hypotension), cough, wheezing, heart beating faster than usual, low oxygen in the blood (hypoxia), throat tightness, runny or stuffy nose, headache, itching, high blood pressure, nausea, vomiting, chills, fever, chest pain, and blurred vision

<u> </u>							
You may ex	perience side	effects from treat	ment				
Side effects are	e an unwanted or	unexpected reaction	to a drug that ca	n occur anywhere	due to the admi	nistration of treatme	ent.
The most comm	ion side effects of D	ARZALEX FASPRO® whe	n used alone inclu	de cold-like sympt	oms (upper respire	atory infection).	
Reactions to	the injection						
		ts who participated in		e clinical studios	% of the 832 patie	nts taking	
		as monotherapy or					
9%		st reactions being mild					
	In these studies.	.8% of the 832 patients	ovporioncod a ro	uppo injection rolat	od roaction with [
		ms included shortness					
		, heart beating faster t					
	nose, headache,	itching, high blood pr	essure, nausea, voi	niting, chills, fever,	and chest pain.		
IMPORIANT	SAFELY INFORM	ATION (CONT)					
The most comm	non side effects of	DARZALEX FASPRO® w	hen used in comb	pination therapy in	clude:		
 tiredness 		• rash		gh blood pressure		nstipation	
 nausea 		 fever 		uscle, bone, and jo		g infection (pneum	
 diarrhea shortness of h 		 cough muscle spasms 		old-like symptoms oper respiratory in		ollen hands, ankles, creased red blood i	
 snormess or c trouble sleep 		 muscle spasms back pain 		pper respiratory in irve damage cau:		creasea rea biooa i unts	cell
 headache 	-9	vomiting		alina, numbness, o		01113	
These are not a	all of the possible si	de effects of DARZALE	X FASPRO®. Call vo	our doctor for med	ical advice abou	it side effects.	
You may repor	side effects to FD/	A at 1-800-FDA-1088.					
Please <u>click here</u>	to read full Prescribit	ng Information for DARZA	LEX FASPRO®. Please	see additional Impo	ortant Safety Informa	ation on pages <u>18-21</u> .	16
DARZALEX For (deratumentab and hypotureria ingeties for subcoherence or Utility)	About multi		Clinical benefits	Expectations for treatment	Important Safety Information	Patient support	Glossary
				•••••			

17N



About multiple myeloma

About **DARZALEX FASPRO®** Clinical **benefits**

(F) **Expectations for** treatment ••••••

Important Safety Information

Patient

support

Side effects (cont)

30-MINUTE DISCUSSION

Use this page to discuss possible side effects of DARZALEX FASPRO®.

Talking points

- In the clinical study comparing DARZALEX FASPRO[®] and DARZALEX[®], nearly 3 times fewer patients experienced infusion reactions with DARZALEX FASPRO® compared with the IV formulation of DAR7ALEX®
 - 13% of the 260 patients who received DARZALEX FASPRO® experienced injection reactions (systemic) as compared with 34% of the 258 patients who received DARZALEX®
- The most common side effects of DARZALEX FASPRO® are cold-like symptoms (upper respiratory tract infection) and changes in blood cell counts
 - Some patients may have skin reactions at or near the injection site (local)
- 8% of patents had a local injection-site reaction with injection site redness (called erythema) being the most frequent
- Tell your healthcare provider if you have any side effects that are bothersome or do not do away
- Remember, these are not all the possible side effects of DARZALEX FASPRO[®]. Call your doctor for medical advice about side effects

🧭 Side effects (cont)

Fewer patients experienced reactions with DARZALEX FASPRO



injection reactions (systemic) as compared with 34% of the 258 patients who received the IV formulation of DARZALEX

The most common side effects of DARZALEX FASPRO® are cold-like symptoms (upper respiratory infection) and changes in blood cell counts. In addition, some patients may have skin reactions at or near the injection site (local). In a clinical trial, 8% of patients had local injection-site reactions with injection site redness (erythema) being the most frequent Tell your healthcare provider if you have any side effects that are bothersome or that do not ao away

These are not all the possible side effects of DARZALEX FASPRO®. Call your doctor for medical advice about side effects

IMPORTANT SAFETY INFORMATION (CONT)

General information about the safe and effective use of DARZALEX FASPRO

edicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Y althcare provider for information about DARZALEX FASPRO® that is written for health professionals.

Active ingredient: daratumumab and hyaluronidase-fihj Inactive ingredients: L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 20, sorbitol,

Please click here to read full Prescribing Information for DARZALEX FASPRO®. Please see additional Im

Tip

DARZALEX Faspro* About multiple

Ask your patient if they have any more questions about DARZALEX FASPRO®. Tell them to make note of any questions that you cannot answer using this guide and to bring them to their next doctor's appointment.

Stress the importance of open communication during visits. Ask patients to keep track of what they notice during and between injections.

18N



About multiple myeloma

About **DARZALEX FASPRO®** Clinical **benefits**

(1) **Expectations for** treatment

Important Safety Information

Patient support

Important Safety Information

15-MINUTE DISCUSSION

30-MINUTE DISCUSSION

This page contains Important Safety Information for patients taking DARZALEX FASPRO[®]. It is important that you review the Important Safety Information with each patient. Emphasize the need for patients to make their doctor aware of any side effect that bothers them or does not go away.



- This is important information for patients who are treated with DARZALEX FASPRO[®];
 as I read through it with you, make a note of any questions you might have
- Remember to be mindful of how you're feeling
- Letting your treatment team know of any side effects that bother you or don't go away is incredibly important

🛛 Tip

Provide patients with a copy of the Important Safety Information and/or the patient brochure. Encourage patients to read through them thoroughly and write down any questions they may have.

				its with multiple my	veloma: wlv diaanosed peo	olo who are olial	bla ta
receive a type of	stem cell transplar	nt that uses their o	wn stem cells (au	tologous stem cell	transplant)		
					ith newly diagnosed tem cell transplant)	I multiple myelon	ia who
 in combination wireceive a type of 	th the medicines I stem cell transplar	enalidomide and nt that uses their o	dexamethasone wn stem cells (au	in people with ne tologous stem cell	wly diagnosed multi transplant) and in p ne prior medicine to	eople whose mu	Itiple
	th the medicines I	oortezomib, thalid	omide, and dexa	amethasone in nev	vly diagnosed peop		
	th the medicines I				e received at least o	ne prior medicin	a to tre
 in combination wi including lenalida 					nave received at lea	ist one prior med	icine,
	th the medicines (carfilzomib and de	xamethasone in	people whose mu	ultiple myeloma has nyeloma	come back or di	d not
 alone in people w or did not respond 					ne inhibitor and an i	mmunomodulat	ory ag
It is not known if DAI				agen.			
IMPORTANT SAF	ETY INFORMAT	ION					
Do not receive DAR		ou have a history	of a severe allerg	ic reaction to dan	atumumab, hyaluror	nidase, or any of	the
		°, tell your healthc	are provider ab	out all of your med	ical conditions, inclu	uding if you:	
 have a history of b 	reathing problem	15					
 have had shingles 	(herpes zoster)					Continued or	next
Please <u>click here</u> to re	ad full Prescribing Ir	formation for DARZA	LEX FASPRO®.				
DARZALEX Faspro	About multiple myeloma	About DARZALEX FASPRO	Clinical	Expectations for treatment	(Monortant Safety	Patient	
(daratumumab and hyskronidese-fihit)			benefits			support	

Your healthcore provider will give you medicines before each dose of DARZALEX FASPRO¹ and after each dose of DARZALEX FASPRO¹ to help reduce the risk of serious allergic reactions and other reactions due to release of certain substances by your body (systemic).
 If you miss any appointments, call your healthcore provider as soon as possible to reschedule your appointment.

• low oxygen in the blood (hypoxig)

∘ eye pain

° nausea

chills

° vomiting

° chest pair

ding, or redness of the skir

blurred vision

Continued on next page

Glossary

UNLAULEX NATION" TWO CODE serious reactions, including: 5 effoxol allegis calcolarion and other serve injection-realised reactions. Serious allergic reactions and reactions due to release certain substances by your body (systemic) that can lead to death can happen with DARALEXFARPRO", Your healthcore pro may temporarily to par completely to preterment with DARALEXFARPOR" by on how a sedior, accellance that your healthcore or get medical help right away if you get any of these symptoms during or after an injection of DARALEXFARPOR".

> ° runny or stuffy nose ° headache

These tests built submittee in a submittee in the submittee of the submittee in the submitt

 Changes in blood lests. DARZALEX FASPRO* can affect the results of blood tests to match your blood type. These changes can last for up to 6 months after your final dase of DARZALEX FASPRO*. Your healthcare provider will do blood tests to match your blood type before you start treatment with DARZALEX FASPRO*. Tell all all your healthcare providers that you are being treated with

itching

 Injection site reactions. Skin reactions at or near the injection site (local), including injection site reactions, can happ DARZALEX FASRO[®]. Symptoms at the site of injection may include liching, swelling, bruking, pain, rash, bleeding, or These reactions sometimes happen more than 24 hours after on injection of DARZALEX FASRO[®].

DARZALEX FASPRO® may cause serious reactions, including:

DARZALEX FASPRO® before receiving blood transfusions.

Please click here to read full Prescribing Information for DARZALEX FASPRO

dizziness or lightheadedness (hypotension)
 throat tightness or irritation

shortness of breath or trouble breathing

• heart beating faster than usual

° cough ° wheezing

DARZALEX Faspro

how ever had an might now how a bepaditis infection as DARIALER FARRO? could could repatite 3 what to become active again. You headhour every failed will check you forging of the infection before, during, and for some time det treatment with DARIALER FARRO? Tell you headhour epipanti a plan to become pegnant. DARIALER FARRO? The plan to plan the become provider right away if you get warsening treadmess or velowing of your skin or while part of your eyes.
 If you become pegnant or think that you may be pegnant during therdment with DARIALER FARRO?

Important Safety Information (cont)

Females who are able to become pregnant should use an effective method of birth control (contraception) during treatment and for 3 months after your last dose of DARIALEX FASPRO*. Talk to your healthcare provider about birth control methods that you can use during this time.

 * Before storing DARFALEE (ARPC⁺) in combination with inclicionide, or pornalidamide, females and males must agree to the instructions in the inclinationide, inclination of the storing of the program.
 The instructionide, main and a pornalidamide EBAS have more information about effective methods of birth control, preparance retries, and blood danation for females who can become preparent.

 Instructurities, manifoldmate such portilationinge such and the frage inclusion and such ensembles as unit a contract, pregnancy legitim, and blood another for females who can become pregnant.
 For males who have female partners who can become pregnant, there is information in the lenalidomide, thaildomide, and bond the portal damate REVS boot speceme donation and how lenalidomide, thaildomide, and portal damate can possible have females.

pormiclionide REX sobult spem donation and how lenalidanide, halidanide, and pormalidanide can pass into human semeare becatteriating or plan to breastless L1 is not howne 1 beALEXLEX.KPR/PPC pass in hoy our breast milk. You shudd not breastless during treatment with DARALEX.FXRPC*, Tak to your healthcare provider about the best way to feed your baby during treatment with DARALEX.FXRPC*.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive DARZALEX FASPRO®?

DARZALEX FASPRO* may be given clone or together with other medicines used to treat multiple myelama.
 DARZALEX FASPRO* will be given to you by your healthcare provider as an injection under the skin in the stomach area (abdamen).
 DARZALEX FASPRO* in lipected over 3 to 5 minute.

Your healthcare provider will decide the time between doses as well as how many treatments you will receive.



decreased red blood ce		when used alone include cold-like symp	otoms (upper respiratory intection
The most common side	effects of DARZALEX FASPRO	* when used in combination therapy incl	ude:
 firedness 	• rash	 high blood pressure 	 constipation
 nausea 	 fever 	 muscle, bone, and joint pain 	 lung infection (pneumonia)
 diarrhea 	 cough 	 cold-like symptoms 	 swollen hands, ankles, or fe
 shortness of breath 	 muscle spasms 	(upper respiratory infection)	 decreased red blood
 trouble sleeping 	 back pain 	 nerve damage causing tingling, 	cell counts
 headache 	 vomiting 	numbness, or pain	
These are not all of the p report side effects to FD/		ALEX FASPRO®. Call your doctor for medic	al advice about side effects. Yo
General information ab	out the safe and effective u	se of DARZALEX FASPRO®	
		ther than those listed in a Patient Informat K FASPRO® that is written for health profess	
Active ingredient: darat	umumab and hyaluronidas	e-fihj	
Inactive ingredients: L-h	istidine, L-histidine hydrochlo	oride monohydrate, L-methionine, polysori	pate 20, sorbitol, water for injecti
Please click here to read	d full Prescribing Information	for DARZALEX FASPRO®.	
cp-143282v10			

Clinical benefits

19N

Glossary



About multiple myeloma

About DARZALEX FASPRO® Clinical benefits

Expectations for treatment

Important Safety Information

DARZALEX Faspro" About multiple (doptimumb and holivenière fit) myelomo

> Patient support

Support for patients and their caregivers

Direct patients to click on the Patient support button in the navigation. Use this page to discuss the patient support program for DARZALEX FASPRO® with Janssen CarePath as well as additional resources available to help them on their treatment journey.

🗩 Talking points

- Support for patients and their caregivers
 - Once you and your doctor have decided that DARZALEX FASPRO[®] is right for you, Janssen CarePath will help you find the resources you may need to get started and stay on track
 - Janssen CarePath will give you information on your insurance coverage, potential out-of-pocket costs, and treatment support, and identify options that may help make your treatment more affordable
 - Call a Janssen CarePath Care Coordinator today at 1-844-55DARZA (1-844-553-2792), Monday-Friday 8:00 AM to 8:00 PM ET, create a Janssen CarePath Account at <u>MyJanssenCarePath.com</u> or visit <u>JanssenCarePath.com/Darzalex-Faspro</u>
- Here are some additional resources available on the website for DARZALEX FASPRO[®], www.darzalex.com/faspro
- Consider using these materials to help you on your treatment journey
- To download the information discussed in this piece and find these resources, visit www.darzalex.com/faspro

withMe	you explore options to lower your	vant cost to get in the way of treatment you need. We can help out-of-pocket cost for DARZALEX FASPRO®.				
withite						
	Visit J&J withMe.com/signup or call 833-JNJ-wMe1 (833-565-9631), Monday through Friday 8:00 AM-8:00 PM ET.					
more about the DARZALEX FASP	hensive resource to learn e treatment experience with RO®.	Watch a patient's experience See another patient's treatment journey with DARZALEX FASPRO*.				
	questions based on your rests to bring to your next	Teadment Calendar Keep track of your dosing schedule and plan with your doctor for your next visit.				

Tip

Patients may consider enrolling in Janssen CarePath patient support for DARZALEX FASPRO® for continual support throughout their treatment journey.

20 N



About multiple myeloma About DARZALEX FASPRO® Clinical benefits Expectations for treatment Important Safety Information Patient support

Glossary

This glossary defines terms that patients may be unfamiliar with. Encourage them to ask you for definitions as you come across the bolded terms in your discussion.

Talking points

- This glossary contains the definitions for the bolded terms that appear throughout this piece
- This is the last page we have to review
- Let your healthcare team know if you have any questions

© Janssen Biotech, Inc. 2024 11/24 cp-270017v4

Johnson&Johnson

💊 DARZALEX **Faspro**® (daratumumab and hyaluronidase-fihi) Injection for subcutaneous use 1,800mg/30,000units

About multiple myeloma


About **DARZALEX FASPRO®** Clinical **benefits** **Expectations for** treatment

Important Safety Information

Glossary

Patient

support



Formulation The body's overreaction to a typically harmless substance The way in which different ingredients are comb to make a medicine.

💷 Glossary

called an allergen. Anything can be an allergen.

the body from infection and disease.

A protein produced by plasma cells that helps protect

Alleraic reaction

Antibody

Hvaluronidase

An ingredient that helps to disperse the disease-fighting medicine in DARZALEX FASPRO® throughout the body.

FOR PATIENTS RECEIVING



Managing your multiple myeloma with DARZALEX FASPRO®

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO®. Please see additional Important Safety Information on pages <u>18-21</u>.



About multiple myeloma About DARZALEX FASPRO® Clinical benefits Expectations for treatment

Important Safety Information

y Patient support

Your journey with multiple myeloma is unique.

For your specific needs, your healthcare team chose a treatment regimen with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj).

This guide will help you learn more about DARZALEX FASPRO® and how it fits into your treatment plan for multiple myeloma. Remember, you are your own best advocate. If you have any concerns about your treatment plan, feel free to ask questions to stay involved.

Any terms in **bold** are defined at the end of this guide in the glossary.

INDICATIONS

What is DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)?

DARZALEX FASPRO® is a prescription medicine used to treat adult patients with multiple myeloma:

- in combination with the medicines bortezomib, lenalidomide, and dexamethasone in newly diagnosed people who are eligible to receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)
- in combination with the medicines bortezomib, melphalan, and prednisone in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)
- in combination with the medicines lenalidomide and dexamethasone in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant) and in people whose multiple myeloma has come back or did not respond to treatment who have received at least one prior medicine to treat multiple myeloma
- in combination with the medicines bortezomib, thalidomide, and dexamethasone in newly diagnosed people who are eligible to receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)

- in combination with the medicines bortezomib and dexamethasone in people who have received at least one prior medicine to treat multiple myeloma
- in combination with the medicines pomalidomide and dexamethasone in people who have received at least one prior medicine, including lenalidomide and a proteasome inhibitor, to treat multiple myeloma
- in combination with the medicines carfilzomib and dexamethasone in people whose multiple myeloma has come back or did not respond to treatment who have received one to three prior medicines to treat multiple myeloma
- alone in people who have received at least three prior medicines, including a proteasome inhibitor and an immunomodulatory agent, or did not respond to a proteasome inhibitor and an immunomodulatory agent

It is not known if DARZALEX FASPRO® is safe and effective in children.

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages <u>18-21</u>.




About multiple myeloma About DARZALEX FASPRO® Clinical benefits Expectations for treatment

Important Safety Information Patient support

Glossary

What is multiple myeloma?

Multiple myeloma is a blood cancer that affects a type of white blood cell called a plasma cell. These white blood cells are found mostly in bone marrow, the soft substance inside some hollow bones where blood cells are made.



Normal, healthy plasma cells are white blood cells that produce **antibodies**. Antibodies are part of the **immune system** and help the body fight infections.

When plasma cells have **DNA** damage, they can overproduce. This can weaken the immune system and can lead to abnormal amounts of **M-protein** that can damage the kidneys.

These damaged (cancerous) plasma cells rapidly spread and replace normal cells with tumors, usually in the bone marrow.

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages <u>18-21</u>.

DARZALEX Faspro[®] (daratumumab and hyaluronidase-fihi) Injection for subcutaneous use | 1,800mg/30,000units About multiple myeloma

About DARZALEX FASPRO® Clinical benefits Expectations for treatment

Important Safety Information

Safety tion **Patient**

support



Over time, multiple myeloma can get worse.



As multiple myeloma progresses, you may start to show more symptoms, or the cancer might start to spread and impact other parts of your body.



To experience the full benefits of your treatment plan, it's important to receive treatment as directed by your doctor and stay on it as long as your doctor determines is appropriate.



If you experience any negative side effects, let your doctor know immediately and you can decide on the next steps together.

Please click here to read full Prescribing Information for DARZALEX FASPRO®. Please see additional Important Safety Information on pages 18-21.

DARZALEX **Faspro**® daratumumab and hyaluronidase–fihi` Injection for subcutaneous use | 1,800mg/30,000units

(F) About multiple myeloma ••


About DARZALEX FASPRO® Clinical **benefits** **Expectations for** treatment

Important Safety Information

Patient support

DARZALEX FASPRO[®] is a prescription medicine used to treat different types of patients with multiple myeloma.

It is given by your healthcare provider as an injection in the subcutaneous tissue (the tissue under the skin) of the stomach.



IMPORTANT SAFETY INFORMATION

Do not receive DARZALEX FASPRO® if you have a history of a severe allergic reaction to daratumumab, hyaluronidase, or any of the ingredients in DARZALEX FASPRO[®]. See below for a complete list of ingredients in DARZALEX FASPRO[®].

Before you receive DARZALEX FASPRO®, tell your healthcare provider about all of your medical conditions, including if you:

- have a history of breathing problems
- have had shingles (herpes zoster)

Please click here to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages 18-21.

DARZALEX Faspro® daratumumab and hvaluronidase-fihi Injection for subcutaneous use | 1,800mg/30,000units

About multiple myeloma

 (\mathbb{N}) About DARZALEX FASPRO®

• 0

Clinical **benefits** **Expectations for** treatment

Important Safety Information

Patient support

Glossary

How does DARZALEX FASPRO[®] work?

DARZALEX FASPRO[®] is made up of 2 main components:

Daratumumab

(pronounced da-ra-tu-mu-mab) is the ingredient that treats multiple myeloma.

(+)

Hyaluronidase

(pronounced hy-a-lur-on-i-dase) helps daratumumab to be injected into the skin and absorbed into the body.

Remember, DARZALEX FASPRO[®] is not chemotherapy. It is an immunotherapy that works with your immune system to fight disease.



Multiple myeloma cells, like other types of cancer, can go unrecognized by your body, which allows cells to grow.



Daratumumab attaches itself to the **CD38 protein** on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.



Daratumumab directly kills multiple myeloma cells and/or allows your immune system to identify and destroy them. Because of the way daratumumab works, it may also affect normal cells.

DARZALEX FASPRO® may cause serious reactions, including:

serious allergic reactions and other severe injection-related reactions, injection site reactions, decreases in blood cell counts, and changes in blood tests.

IMPORTANT SAFETY INFORMATION (CONT)

• have ever had or might now have a hepatitis B infection as DARZALEX FASPRO[®] could cause hepatitis B virus to become active again. Your healthcare provider will check you for signs of this infection before, during, and for some time after treatment with DARZALEX FASPRO[®]. Tell your healthcare provider right away if you get worsening tiredness or yellowing of your skin or white part of your eyes.

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages <u>18-21</u>.

DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) Injection for subcutaneous use | 1,800mg/30,000units

About multiple myeloma About DARZALEX FASPRO®

••

Clinical benefits Expectations for treatment

Important Safety Information

ety Patient support

Glossary

Monotherapy study

A clinical study confirmed that DARZALEX FASPRO® gave patients results comparable to the intravenous (IV) formulation of DARZALEX® (daratumumab) in treating multiple myeloma when used as monotherapy (by itself). DARZALEX® is an IV infusion with the same disease-fighting ingredient as DARZALEX FASPRO® that is proven effective in multiple combinations to fight multiple myeloma.

Patients in this study had multiple myeloma and:

- Received at least 3 prior medicines OR
- Did not respond to a proteasome inhibitor (PI) and an immunomodulatory agent

522 patients in this study

222 222 DARZALEX[®] (monotherapy) DARZALEX FASPRO® (monotherapy) 259 patients 263 patients

IMPORTANT SAFETY INFORMATION (CONT)

- are pregnant or plan to become pregnant. DARZALEX FASPRO® may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with DARZALEX FASPRO®.
- ° Females who are able to become pregnant should use an effective method of birth control (contraception) during treatment and for 3 months after your last dose of DARZALEX FASPRO®. Talk to your healthcare provider about birth control methods that you can use during this time.

Please click here to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages 18-21.

 (\mathbb{Q})

Clinical

benefits 000



About multiple myeloma

About **DARZALEX FASPRO®** **Expectations for** treatment

Important Safety Information

Patient support

Glossary



DARZALEX FASPRO® (monotherapy)



About 4 of 10 patients responded to treatment with DARZALEX FASPRO® VS 37%

DARZALEX[®] (monotherapy)

About 4 of 10 patients responded to treatment with DARZALEX®

8

Responses in patients treated with DARZALEX FASPRO® were consistent with those treated with DARZALEX®, a proven treatment for multiple myeloma

IMPORTANT SAFETY INFORMATION (CONT)


- ^o Before starting DARZALEX FASPRO[®] in combination with lenalidomide, thalidomide, or pomalidomide, females and males must agree to the instructions in the lenalidomide, thalidomide, or pomalidomide REMS program.
 - The lenalidomide, thalidomide, and pomalidomide REMS have more information about effective methods of birth control, pregnancy testing, and blood donation for females who can become pregnant.
 - For males who have female partners who can become pregnant, there is information in the lenalidomide, thalidomide, and pomalidomide REMS about sperm donation and how lenalidomide, thalidomide, and pomalidomide can pass into human semen.

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages <u>18-21</u>.



Combination therapy study

Several studies have evaluated combination therapies using DARZALEX FASPRO[®]. These studies confirmed that DARZALEX FASPRO[®] is effective when used in combination with other medicines (DVMP and DRd results are shown here).



IMPORTANT SAFETY INFORMATION (CONT)

• are breastfeeding or plan to breastfeed. It is not known if DARZALEX FASPRO® passes into your breast milk. You should not breastfeed during treatment with DARZALEX FASPRO®. Talk to your healthcare provider about the best way to feed your baby during treatment with DAR7ALEX FASPRO®

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please click here to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages 18-21.

 (\mathbb{Q})

Clinical

benefits $\bullet \bullet \bullet \circ$



About multiple myeloma

About **DARZALEX FASPRO®** **Expectations for** treatment

Important Safety Information

support

Patient

Glossary



Results from the combination therapy study

DVMP



About 9 of 10 patients responded to treatment with DARZALEX *FASPRO®* in combination with bortezomib, melphalan, and prednisone

DRd



About 9 of 10 patients responded to treatment with DARZALEX *FASPRO®* in combination with lenalidomide and dexamethasone

10

Ask your doctor for more information about how they expect you will respond to your prescribed regimen of DARZALEX FASPRO®

IMPORTANT SAFETY INFORMATION (CONT)

How will I receive DARZALEX FASPRO®?

- DARZALEX FASPRO® may be given alone or together with other medicines used to treat multiple myeloma.
- DARZALEX FASPRO® will be given to you by your healthcare provider as an injection under the skin in the stomach area (abdomen).
- DARZALEX FASPRO® is injected over 3 to 5 minutes.
- Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
- Your healthcare provider will give you medicines before each dose of DARZALEX FASPRO® and after each dose of DARZALEX FASPRO® to help reduce the risk of serious allergic reactions and other reactions due to release of certain substances by your body (systemic).

If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages <u>18-21</u>.

CARZALEX Faspro DARZALEX Faspro (daratumumab and hyaluronidase-fihi) Injection for subcutaneous use 1,800mg/30,000units About multi myelom	Q Clinical benefits	Expectations for treatment	Important Safety Information	Patient support	Glossary



Your treatment checklist for DARZALEX FASPRO®

Before your injection

Tell vour doctor about:

- All of your medical conditions
- All of the medications you are taking

Ask your doctor about your treatment goals with DARZALEX FASPRO®. For example:

- How will you know this treatment is working?
- What **response** are you hoping to see with DARZALEX FASPRO®?
- How long should I expect to stay on this treatment regimen?

IMPORTANT SAFETY INFORMATION (CONT)

DARZALEX FASPRO® may cause serious reactions, including:

- Serious alleraic reactions and other severe injection-related reactions. Serious alleraic reactions and reactions due to release of certain substances by your body (systemic) that can lead to death can happen with DARZALEX FASPRO®. Your healthcare provider may temporarily stop or completely stop treatment with DARZALEX FASPRO® if you have a serious reaction. Tell your healthcare provider or get medical help right away if you get any of these symptoms during or after an injection of DARZALEX FASPRO®.
- shortness of breath or trouble breathing
- dizziness or lightheadedness (hypotension)
- couah
- wheezing
- heart beating faster than usual

- low oxygen in the blood (hypoxia)
- throat tightness or irritation
- runny or stuffy nose
- headache
- itchina

- high blood pressure
- eve pain
- ° nausea
- vomitina
- chills

- fever
- chest pain
- blurred vision
- Please click here to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages 18-21.



About multiple myeloma

About **DARZALEX FASPRO®** Clinical **benefits**

£7 **Expectations for** treatment

Important Safety Information

Patient support

Glossary

11

Pay attention to how you feel Tell your doctor immediately if you experience any side effects or reactions


Day of your injection

- Wear comfortable clothing that is loose around the waist
- Set aside enough time
- Take the medications your doctor will give you prior to the injection
- Tell your healthcare providers and personnel at blood transfusion centers that you are taking DARZALEX FASPRO®

After your injection

Before your injection

Before you receive DARZALEX FASPRO®, tell your healthcare provider:



IMPORTANT SAFETY INFORMATION (CONT)

• Injection site reactions. Skin reactions at or near the injection site (local), including injection site reactions, can happen with DARZALEX FASPRO®. Symptoms at the site of injection may include itching, swelling, bruising, pain, rash, bleeding, or redness of the skin. These reactions sometimes happen more than 24 hours after an injection of DARZALEX FASPRO®.

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages <u>18-21</u>.



About multiple myeloma About DARZALEX FASPRO®

Clinical benefits Expectations for treatment

Important Safety Information

Patient support Glossary

Preparing for your injection

If this is the first time you are receiving treatment with DARZALEX FASPRO[®], you may have questions about what it's like, and what you need to do to prepare. Here is some information that may help.



Wear comfortable clothing that is loose around the waist: DARZALEX FASPRO® is injected about 3 inches to the left or right of the belly button.



Set aside enough time: For the first few injections, your healthcare provider may want you to stay afterward to monitor for a reaction to the injection.



You will be given medicines to help reduce the risk of side effects to the injection, such as:

- Antihistamines to prevent an allergic reaction
- Corticosteroids to prevent inflammation
- Acetaminophen or similar medicine to reduce fever

IMPORTANT SAFETY INFORMATION (CONT)



You will be given a physical exam before the injection: This includes checking your pulse and blood pressure.



Tell your healthcare provider and blood transfusion centers/personnel that you are taking DARZALEX FASPRO®.

DARZALEX FASPRO® can affect the results of blood tests to match your blood type. These changes can last for up to 6 months after your final dose of DARZALEX FASPRO®. Your healthcare provider will do blood tests to match your blood type before you start treatment with DARZALEX FASPRO®. Tell all your healthcare providers that you are being treated with DARZALEX FASPRO® before receiving blood transfusions.

• Decreases in blood cell counts. DARZALEX FASPRO® can decrease white blood cell counts, which help fight infections, and blood cells called platelets, which help to clot blood. Decreases in blood cell counts are common with DARZALEX FASPRO® but can be severe. Your healthcare provider will check your blood cell counts during treatment with DARZALEX FASPRO®. Tell your healthcare provider if you develop fever or have signs of bruising or bleeding.

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages <u>18-21</u>.



About multiple myeloma About DARZALEX FASPRO®

Clinical benefits Expectations for treatment


Important Safety Information

Safety ation


Patient support

Glossary






Your healthcare provider will **prepare the injection**



Your healthcare provider will determine where to inject and prepare the chosen area, rotating injection sites in the stomach area each time you receive an injection



The injection takes **about 3 to 5 minutes** to be given.* The medicine is injected into the subcutaneous tissue (the tissue under the skin) of the stomach.

*This refers to the injection administration time and does not account for all aspects of treatment.

IMPORTANT SAFETY INFORMATION (CONT)

• Changes in blood tests. DARZALEX FASPRO[®] can affect the results of blood tests to match your blood type. These changes can last for up to 6 months after your final dose of DARZALEX FASPRO[®]. Your healthcare provider will do blood tests to match your blood type before you start treatment with DARZALEX FASPRO[®]. Tell all of your healthcare providers that you are being treated with DARZALEX FASPRO[®] before receiving blood transfusions.

The most common side effects of DARZALEX FASPRO® when used alone include cold-like symptoms (upper respiratory infection) and decreased red blood cell counts.

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages <u>18-21</u>.



About multiple myeloma About DARZALEX FASPRO® Clinical benefits Expectations for treatment

Important Safety Information

fety Patient n support Glossary





Pay attention to how you feel and let the healthcare staff know about any discomfort during or after treatment, and especially during the first and second injections. It could mean you may be having a reaction to the treatment.

Do not receive DARZALEX FASPRO® if you have a history of a severe allergic reaction to daratumumab, hyaluronidase, or any of the ingredients in DARZALEX FASPRO®. See below for a complete list of ingredients in DARZALEX FASPRO®.

Your healthcare provider may want you to remain in the office to watch for any side effects.

Serious allergic reactions and other severe injection-related reactions. Serious allergic reactions and reactions due to release of certain substances by your body (systemic) that can lead to death can happen with DARZALEX FASPRO[®]. Your healthcare provider may temporarily stop or completely stop treatment with DARZALEX FASPRO[®] if you have a serious reaction. Tell your healthcare provider or get medical help right away if you get any of these symptoms during or after an injection of DARZALEX FASPRO[®].

- shortness of breath or trouble breathing
- dizziness or lightheadedness (hypotension)
- ∘ cough
- wheezing
- heart beating faster than usual

- low oxygen in the blood (hypoxia)
- throat tightness or irritation
 runny or stuffy nose
- o funny of sturry hose
- headache
- itching

- high blood pressure
- ° eye pain
- nausea
- vomitingchills
- ° Chills

- fever
- chest pain
- blurred vision

Injection site reactions. Skin reactions at or near the injection site (local), including injection site reactions, can happen with DARZALEX FASPRO[®]. Symptoms at the site of injection may include itching, swelling, bruising, pain rash, bleeding, or redness of the

itching, swelling, bruising, pain, rash, bleeding, or redness of the skin. These reactions sometimes happen more than 24 hours after an injection of DARZALEX FASPRO[®].

Following the injection, you will also be given oral corticosteroids to reduce the risk of delayed reactions due to the administration of DARZALEX FASPRO[®].

It's important to stay on treatment as directed by your doctor to feel the full benefits of treatment. Discuss next steps with your doctor if you experience any reactions to the injection.

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages <u>18-21</u>.



About multiple myeloma About DARZALEX FASPRO® Clinical benefits Expectations for treatment

Important Safety Information

Patient support

Glossary



You may experience side effects from treatment

Side effects are an unwanted or unexpected reaction to a drug that can occur anywhere due to the administration of treatment.

The most common side effects of DARZALEX FASPRO® when used alone include cold-like symptoms (upper respiratory infection).

Reactions to the injection



- Among all patients who participated in DARZALEX FASPRO[®] clinical studies, **9% of the 832 patients taking** DARZALEX FASPRO[®] as monotherapy or as part of combination therapy experienced a reaction related to the injection, with most reactions being mild to moderate and occurring after the first injection.
- In these studies, **0.8% of the 832 patients** experienced a severe injection-related reaction with DARZALEX FASPRO[®]. Signs and symptoms included shortness of breath or trouble breathing, dizziness or lightheadedness (hypotension), cough, wheezing, heart beating faster than usual, low oxygen in the blood (hypoxia), throat tightness, runny or stuffy nose, headache, itching, high blood pressure, nausea, vomiting, chills, fever, and chest pain.

IMPORTANT SAFETY INFORMATION (CONT)

The most common side effects of DARZALEX FASPRO® when used in combination therapy include:

tirednessnausea

diarrhea

headache

shortness of breath

trouble sleeping

- rash
- fever
 - cough
 - muscle spasms
 - back pain
 - vomiting

- high blood pressure
- muscle, bone, and joint pain
- cold-like symptoms (upper respiratory infection)
- nerve damage causing tingling, numbness, or pain
- constipation
- lung infection (pneumonia)
- swollen hands, ankles, or feet
- decreased red blood cell counts

These are not all of the possible side effects of DARZALEX FASPRO[®]. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages <u>18-21</u>.



About multiple myeloma

About DARZALEX FASPRO® Clinical benefits Expectations for treatment

Important Safety Information Patient support

Glossary



Fewer patients experienced reactions with DARZALEX FASPRO®



In a clinical study that compared DARZALEX FASPRO[®] (monotherapy) with the IV formulation of DARZALEX[®] (monotherapy), **13% of the 260 patients** who received DARZALEX FASPRO[®] experienced **nearly 3 times fewer injection reactions** (systemic) as compared with **34% of the 258 patients** who received the IV formulation of DARZALEX[®].

The most common side effects of DARZALEX FASPRO® are cold-like symptoms (upper respiratory infection) and changes in blood cell counts. In addition, some patients may have skin reactions at or near the injection site (local). In a clinical trial, 8% of patients had local injection-site reactions with injection site redness (erythema) being the most frequent.

Tell your healthcare provider if you have any side effects that are bothersome or that do not go away.

These are not all the possible side effects of DARZALEX FASPRO®. Call your doctor for medical advice about side effects.

IMPORTANT SAFETY INFORMATION (CONT)

General information about the safe and effective use of DARZALEX FASPRO®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about DARZALEX FASPRO[®] that is written for health professionals.

Active ingredient: daratumumab and hyaluronidase-fihj

Inactive ingredients: L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 20, sorbitol, water for injection

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages <u>18-21</u>.



About multiple myeloma About DARZALEX FASPRO® Clinical benefits Expectations for treatment

Important Safety Information Patient support

Glossary

What is DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)?

DARZALEX FASPRO® is a prescription medicine used to treat adult patients with multiple myeloma:

- in combination with the medicines bortezomib, lenalidomide, and dexamethasone in newly diagnosed people who are eligible to receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)
- in combination with the medicines bortezomib, melphalan, and prednisone in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)
- in combination with the medicines lenalidomide and dexamethasone in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant) and in people whose multiple myeloma has come back or did not respond to treatment who have received at least one prior medicine to treat multiple myeloma
- in combination with the medicines bortezomib, thalidomide, and dexamethasone in newly diagnosed people who are eligible to receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)
- in combination with the medicines bortezomib and dexamethasone in people who have received at least one prior medicine to treat multiple myeloma
- in combination with the medicines pomalidomide and dexamethasone in people who have received at least one prior medicine, including lenalidomide and a proteasome inhibitor, to treat multiple myeloma
- in combination with the medicines carfilzomib and dexamethasone in people whose multiple myeloma has come back or did not respond to treatment who have received one to three prior medicines to treat multiple myeloma
- alone in people who have received at least three prior medicines, including a proteasome inhibitor and an immunomodulatory agent, or did not respond to a proteasome inhibitor and an immunomodulatory agent

It is not known if DARZALEX FASPRO® is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not receive DARZALEX FASPRO® if you have a history of a severe allergic reaction to daratumumab, hyaluronidase, or any of the ingredients in DARZALEX FASPRO®.

Before you receive DARZALEX FASPRO®, tell your healthcare provider about all of your medical conditions, including if you:

- have a history of breathing problems
- have had shingles (herpes zoster)

Continued on next page

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO[®].



About DARZALEX FASPRO® Clinical benefits Expectations for treatment Important Safety Information

Patient support

Glossary

Important Safety Information (cont)

- have ever had or might now have a hepatitis B infection as DARZALEX FASPRO® could cause hepatitis B virus to become active gagin. Your healthcare provider will check you for signs of this infection before, during, and for some time after treatment with DARZALEX FASPRO®. Tell your healthcare provider right away if you get worsening tiredness or yellowing of your skin or white part of your eyes.
- are pregnant or plan to become pregnant. DARZALEX FASPRO® may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with DARZALEX FASPRO[®].
- Females who are able to become pregnant should use an effective method of birth control (contraception) during treatment and for 3 months after your last dose of DARZALEX FASPRO®. Talk to your healthcare provider about birth control methods that you can use during this time.
- Before starting DARZALEX FASPRO® in combination with lenalidomide, thalidomide, or pomalidomide, females and males must agree to the instructions in the lenalidomide, thalidomide, or pomalidomide REMS program.
- The lenalidomide, thalidomide, and pomalidomide REMS have more information about effective methods of birth control. pregnancy testing, and blood donation for females who can become pregnant.
- For males who have female partners who can become pregnant, there is information in the lenalidomide, thalidomide, and pomalidomide REMS about sperm donation and how lenalidomide, thalidomide, and pomalidomide can pass into human semen.
- are breastfeeding or plan to breastfeed. It is not known if DARZALEX FASPRO® passes into your breast milk. You should not breastfeed during treatment with DARZALEX FASPRO®. Talk to your healthcare provider about the best way to feed your baby during treatment with DARZALEX FASPRO[®].

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive DARZALEX FASPRO®?

- DARZALEX FASPRO® may be given alone or together with other medicines used to treat multiple myeloma.
- DARZALEX FASPRO® will be given to you by your healthcare provider as an injection under the skin in the stomach area (abdomen).
- DARZALEX FASPRO® is injected over 3 to 5 minutes.
- Your healthcare provider will decide the time between doses as well as how many treatments you will receive.

Please click here to read full Prescribing Information for DARZALEX FASPRO®. DARZALEX **Faspro**° **Expectations for** About multiple Patient About Clinical Glossary **Important Safety** daratumumab and hvaluronidase-fihi myeloma **DARZALEX FASPRO®** treatment **benefits** support Injection for subcutaneous use | 1,800mg/30,000units Information ••••

Continued on next page

Important Safety Information (cont)

• Your healthcare provider will give you medicines before each dose of DARZALEX FASPRO[®] and after each dose of DARZALEX FASPRO[®] to help reduce the risk of serious allergic reactions and other reactions due to release of certain substances by your body (systemic).

If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

DARZALEX FASPRO® may cause serious reactions, including:

• Serious allergic reactions and other severe injection-related reactions. Serious allergic reactions and reactions due to release of certain substances by your body (systemic) that can lead to death can happen with DARZALEX FASPRO[®]. Your healthcare provider may temporarily stop or completely stop treatment with DARZALEX FASPRO[®] if you have a serious reaction. Tell your healthcare provider or get medical help right away if you get any of these symptoms during or after an injection of DARZALEX FASPRO[®].

 shortness of breath or trouble breathing 	 low oxygen in the blood (hypoxia) 	 high blood pressure 	° fever
 dizziness or lightheadedness (hypotension) 	 throat tightness or irritation 	∘ eye pain	° chest pain
° cough	° runny or stuffy nose	° nausea	 blurred vision
° wheezing	° headache	 vomiting 	
 heart beating faster than usual 	• itching	• chills	

- Injection site reactions. Skin reactions at or near the injection site (local), including injection site reactions, can happen with DARZALEX FASPRO®. Symptoms at the site of injection may include itching, swelling, bruising, pain, rash, bleeding, or redness of the skin. These reactions sometimes happen more than 24 hours after an injection of DARZALEX FASPRO®.
- Decreases in blood cell counts. DARZALEX FASPRO[®] can decrease white blood cell counts, which help fight infections, and blood cells called platelets, which help to clot blood. Decreases in blood cell counts are common with DARZALEX FASPRO[®] but can be severe. Your healthcare provider will check your blood cell counts during treatment with DARZALEX FASPRO[®]. Tell your healthcare provider if you develop fever or have signs of bruising or bleeding.
- Changes in blood tests. DARZALEX FASPRO[®] can affect the results of blood tests to match your blood type. These changes can last for up to 6 months after your final dose of DARZALEX FASPRO[®]. Your healthcare provider will do blood tests to match your blood type before you start treatment with DARZALEX FASPRO[®]. Tell all of your healthcare providers that you are being treated with DARZALEX FASPRO[®] before receiving blood transfusions.



Important Safety Information (cont)

The most common side effects of DARZALEX FASPRO® when used alone include cold-like symptoms (upper respiratory infection) and decreased red blood cell counts.

The most common side effects of DARZALEX FASPRO® when used in combination therapy include:

- tiredness
- nausea
- diarrhea

headache

• shortness of breath

trouble sleeping

• cough

• rash

• fever

- muscle spasms
- back pain
- vomiting

- high blood pressure
- muscle, bone, and joint pain
- cold-like symptoms (upper respiratory infection)
- nerve damage causing tingling, numbness, or pain
- constipation
- lung infection (pneumonia)
- swollen hands, ankles, or feet
- decreased red blood
- cell counts

These are not all of the possible side effects of DARZALEX FASPRO[®]. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of DARZALEX FASPRO®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about DARZALEX FASPRO® that is written for health professionals.

Active ingredient: daratumumab and hyaluronidase-fihj

Inactive ingredients: L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 20, sorbitol, water for injection

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO®.

cp-143282v10



About DARZALEX FASPRO® Clinical benefits Expectations for treatment

Important Safety Information

Patient support

Glossary



Once you and your doctor have decided that DARZALEX FASPRO[®] is right for you, J&J withMe will help you find the resources you may need to get started and stay on track.

At Johnson & Johnson, we don't want cost to get in the way of treatment you need. We can help you explore options to lower your out-of-pocket cost for DARZALEX FASPRO[®].

Visit J&J withMe.com/signup or call 833-JNJ-wMe1 (833-565-9631), Monday through Friday 8:00 AM–8:00 PM ET.

Additional resources available online

If you're looking for more information about DARZALEX FASPRO[®], visit <u>www.darzalex.com/faspro</u> for useful tools and materials to help you on your treatment journey:



Patient Brochure

Use this comprehensive resource to learn more about the treatment experience with DARZALEX FASPRO[®].



Watch a patient's experience

See another patient's treatment journey with DARZALEX FASPRO[®].

Doctor Conversation Starter Guide	
Multi Link and Linker (1976) " (the desired and further and the first of the second sec	

Doctor Conversation Starter

Create a list of questions based on your needs and interests to bring to your next doctor's appointment.

1	
	My DARZALEX FASPEO" Dosing Colendor
	NEXTONS Mark MARKET STORY "percention of a set function of the STOP" Mark Market Story and the second set of the set of the second set of the second Market Story and the second set of the second second set of the second second set of the Market Story and the second second second second second second second se
	E DE LA REPUBLICATION DE DESTINUTION La resultation de la construcción de la construcción de la construcción de la construcción de la construcción la construcción de la construcción de la construcción de la construcción de la construcción de la construcció
	the second secon

Treatment Calendar

Keep track of your dosing schedule and plan with your doctor for your next visit.

Please click here to read full Prescribing Information for DARZALEX FASPRO®. Please see additional Important Safety Information on pages 18-21.



About multiple myeloma About DARZALEX FASPRO® Clinical benefits Expectations for treatment

Important Safety Information Patient support

Glossary



Allergic reaction

The body's overreaction to a typically harmless substance called an allergen. Anything can be an allergen.

Antibody

A protein produced by plasma cells that helps protect the body from infection and disease.

CD38

A protein found on the surface of certain cells and in high numbers on myeloma cells.

Chemotherapy

A chemical drug that stops the growth of cancer cells, either by killing them or by stopping them from dividing. Chemotherapy may be given by mouth, injection or infusion, or on the skin, depending on the type and stage of the cancer being treated. It may be given alone or with other treatments, such as surgery, radiation therapy, or biologic therapy.

Combination therapy

Use of more than one treatment to treat a certain disease or condition.

DNA

Deoxyribonucleic acid, the main component of chromosomes, and the carrier of genetic information.

Formulation

The way in which different ingredients are combined to make a medicine.

Hyaluronidase

An ingredient that helps to disperse the disease-fighting medicine in DARZALEX FASPRO® throughout the body.

Immune system

Several types of cells and organs that work together to help the body fight infections and other diseases.

Immunomodulatory agents

Drugs that change a patient's immune response by enhancing or suppressing the immune system.

Immunotherapy

Drugs that stimulate the immune system to help treat or prevent disease.

Injection reaction

A response of the skin and subcutaneous tissues to any substance introduced with a needle.

Monotherapy

Use of one type of treatment to treat a certain disease or condition.

Please click here to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages <u>18-21</u>.

DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) Injection for subcutaneous use | 1,800mg/30,000units

About multiple myeloma About DARZALEX FASPRO® Clinical benefits Expectations for treatment Important Safety Information Patient support Glossary

• 0



M-protein

An abnormal antibody made by myeloma cells that does not fight germs. Also called monoclonal protein.

Multiple myeloma

A type of cancer formed by cancerous (also called "malignant") plasma cells. Plasma cells are found in the bone marrow.

Proteasome inhibitors

Drugs that slow down cancer cell growth by interfering with processes that play a role in cell function.

Protein

A molecule made up of amino acids that is needed for the body to function properly. Proteins are the basis of skin, hair, and other substances in the body.

Regimen

A plan for treating a condition, such as multiple myeloma. A treatment regimen may use only one medication or it may use several medications together.

Response in multiple myeloma

A measurement made during or after treatment that measures the decrease in the extent of myeloma disease.

Side effect

An unwanted or unexpected reaction to a drug. Side effects can vary from minor problems like a runny nose to life-threatening events, such as an increased risk of a heart attack. Sometimes referred to as an adverse event.

Please <u>click here</u> to read full Prescribing Information for DARZALEX FASPRO[®]. Please see additional Important Safety Information on pages <u>18-21</u>.

© Janssen Biotech, Inc. 2024 11/24 cp-196997v6

Johnson&Johnson

CONTRACTION OF CONTRACT OF

About multiple myeloma About DARZALEX FASPRO® Clinical benefits Expectations for treatment

Important Safety Information

y Patient support (U) Glossary

• •